ACADIA Pharmaceuticals Inc. (ACAD)
Develops medicines treating brain disorders like Parkinson's psychosis and Rett syndrome.
$26.01+0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+10.5%
The outlook
ACAD is trading near multi-month highs with most analysts rating it a buy. The stock sits roughly three-quarters of the way up its 52-week range, and the average analyst price target sits about 27% above the current price. A trailing P/E of 11.8 reflects relatively modest valuation compared to recent momentum.
What’s behind the score
Analyst consensusBuy — 1.8 avg of 20 analysts
Price trendAbove its 50- & 200-day averages
52-week range73% of the way from its 52-week low to high
Price targetAvg target +27% vs current price
Analyst price target
~12-month · 20 analysts$32.95average target+26.7% vs now
Now $26.01
Low $17.00High $45.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$4.45B
52-wk high
$28.35
52-wk low
$19.69
50-day avg
$23.23
200-day avg
$23.52
Trailing P/E
11.8